持久性含氟聚合物药物洗脱支架与裸金属支架预防颅内支架内再狭窄的比较
这项多中心随机试验纳入156例症状性颅内动脉粥样硬化性狭窄患者,比较持久性含氟聚合物药物洗脱支架与裸金属支架。药物洗脱支架组1年支架内再狭窄率为2.9%,裸金属支架组为27.9%,药物洗脱支架显著降低再狭窄风险。
要点
- 症状性颅内动脉粥样硬化性狭窄患者中,药物洗脱支架组1年支架内再狭窄率为2.9%,裸金属支架组为27.9%。
- 该试验达到目前颅内药物洗脱支架随机试验中报告的最低支架内再狭窄率。
- 持久性含氟聚合物药物洗脱支架可能是减少支架内再狭窄的有前景的器械选择。
核心结论
- 在症状性颅内动脉粥样硬化性狭窄患者中,持久性含氟聚合物药物洗脱支架较裸金属支架显著降低1年支架内再狭窄率。
研究设计与样本
- 多中心随机试验,纳入156例症状性颅内动脉粥样硬化性狭窄患者。
主要发现
- 药物洗脱支架组1年支架内再狭窄率为2.9%,裸金属支架组为27.9%。
关键数值与推荐
- 药物洗脱支架组1年支架内再狭窄率2.9% vs 裸金属支架组27.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Although drug-eluting stents (DES) reduce the risk of in-stent restenosis (ISR) compared with bare-metal stents (BMS) in symptomatic intracranial atherosclerotic stenosis (ICAS), the reported 1-year ISR rate (9.5%) of current intracranial DES remains higher than that reported in coronary practice (2.5%–4.9%). WHAT THIS STUDY ADDS In this multicentre randomised trial of 156 patients with symptomatic ICAS, durable fluoropolymer DES significantly reduced the 1-year ISR rate to 2.9% versus 27.9% with BMS, achieving the lowest ISR rate reported in an intracranial DES randomised trial to date. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Durable fluoropolymer DES may be a promising device option for reducing ISR and providing a rationale for future randomised controlled trials comparing endovascular treatment with aggressive medical management in high-risk ICAS. Introduction Intracranial atherosclerotic stenosis (ICAS) is a leading...
引用
- Journal of Neurology, Neurosurgery and Psychiatry:Durable fluoropolymer drug-eluting stent versus bare-metal stent for the prevention of intracranial in-stent restenosis
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。